SCHEMBL2171901

SCHEMBL2171901

CCOC(=O)CON=Cc1cc(Cl)c(Oc2ccc(OC)c(C(C)CC)c2)c(Cl)c1

nearest known ligand 0.45

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
THRB P10828 8/20 0.45
RORC P51449 7/20 0.45
GAA P10253 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
THRA P10827 3/20 0.38
LMNA P02545 3/20 0.37
SMN1; SMN2 Q16637 2/20 0.37
KDM4E B2RXH2 1/20 0.37
HPGD P15428 1/20 0.37
KMT2A Q03164 1/20 0.37
GALR3 O60755 1/20 0.37
NR2F2 P24468 1/20 0.37
RAB9A P51151 1/20 0.37
ALDH1A1 P00352 2/20 0.37
CYP1A2 P05177 1/20 0.37
CYP3A4 P08684 1/20 0.37
PKM P14618 1/20 0.37
CYP2C19 P33261 1/20 0.37
HTT P42858 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16495805 1.00 THRB (0.45) THRBRORCGAAL3MBTL1THRA
SCHEMBL2169290 0.93 RORC (0.54) THRBRORCGAAL3MBTL1THRA
SCHEMBL16496609 0.93 RORC (0.54) THRBRORCGAAL3MBTL1THRA
SCHEMBL2169639 0.89 MAPK1 (0.39) THRBGAAL3MBTL1THRALMNA
SCHEMBL16496219 0.89 MAPK1 (0.39) THRBGAAL3MBTL1THRALMNA
SCHEMBL2169929 0.88 THRB (0.46) THRBRORCGAAL3MBTL1THRA
SCHEMBL2169926 0.88 THRB (0.46) THRBRORCGAAL3MBTL1THRA
SCHEMBL16496560 0.82 THRB (0.54) THRBRORCTHRALMNASMN1; SMN2
SCHEMBL16496559 0.82 THRB (0.54) THRBRORCTHRALMNASMN1; SMN2
SCHEMBL2182856 0.82 THRB (0.42) THRBRORCGAAL3MBTL1THRA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110301200-A1 THYROID RECEPTOR LIGANDS CADILA HEALTHCARE LIMITED (IN) 2011-12-08 US claimed
EP-2346814-A2 THYROID RECEPTOR LIGANDS Cadila Healthcare Limited (IN) 2011-07-27 EP claimed
WO-2010049946-A2 THYROID RECEPTOR LIGANDS CADILA HEALTHCARE LIMITED (IN) 2010-05-06 WO claimed
US-20110301200-A1 THYROID RECEPTOR LIGANDS CADILA HEALTHCARE LIMITED (IN) 2011-12-08 US disclosed
EP-2346814-A2 THYROID RECEPTOR LIGANDS Cadila Healthcare Limited (IN) 2011-07-27 EP disclosed
WO-2010049946-A2 THYROID RECEPTOR LIGANDS CADILA HEALTHCARE LIMITED (IN) 2010-05-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110301200-A1 THYROID RECEPTOR LIGANDS TSHR, THRB, THRA THRB 2/4885RORC 79/4885GAA 4591/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.